NCT01686958View on ClinicalTrials.gov

Safety Study of MRI-guided Transurethral Ultrasound Ablation of Prostate Tissue to Treat Localized Prostate Cancer

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 13, 2013

Primary Completion Date

March 23, 2015

Study Completion Date

June 11, 2019

Conditions
Prostate Cancer
Interventions
DEVICE

MR-Guided Transurethral US Ablation of Prostate Tissue

The technology is developed to treat patients with organ confined prostate cancer. The therapeutic endpoint of this technology is thermal coagulation of prostate tissue.

Trial Locations (3)

48073

William Beaumont Hospital, Royal Oak

69120

German Cancer Research Center (DKFZ), Heidelberg

N6A 5W9

London Health Science Centre, London

All Listed Sponsors
lead

Profound Medical Inc.

OTHER

NCT01686958 - Safety Study of MRI-guided Transurethral Ultrasound Ablation of Prostate Tissue to Treat Localized Prostate Cancer | Biotech Hunter | Biotech Hunter